Marc van Dijk

Company: MiNK Therapeutics

Job title: Chief Scientific Officer

Seminars:

Targeting Neoantigens with Invariant Natural Killer T Cells 1:00 pm

MiNK therapeutics is developing iNKT-based allogeneic cell therapy products for cancer. Invariant Natural Killer T cells (iNKT) recognize glycolipids presented on CD1d through their invariant TCR. iNKT cells can be engineered to stably express a 2nd TCR, and both TCRs are fully functional We are developing a portfolio of phospho-peptide neoantigen-specific TCRs for iNKT-based applicationsRead more

day: Day Two